APA (7th ed.) Citation

SW, K., AN, W., JD, G., KR, T., K, W., AA, H., . . . V, S. (2019). Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine. The Journal of pharmacology and experimental therapeutics, 371(2), 487. https://doi.org/10.1124/jpet.118.255661

Chicago Style (17th ed.) Citation

SW, Kaski, et al. "Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant That Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine." The Journal of Pharmacology and Experimental Therapeutics 371, no. 2 (2019): 487. https://doi.org/10.1124/jpet.118.255661.

MLA (9th ed.) Citation

SW, Kaski, et al. "Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant That Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine." The Journal of Pharmacology and Experimental Therapeutics, vol. 371, no. 2, 2019, p. 487, https://doi.org/10.1124/jpet.118.255661.